Mylan N.V. (Nasdaq: MYL) today announced the U.S. launch of Memantine Hydrochloride Tablets USP, 5 mg and 10 mg, which is the generic version of Forest's Namenda ® Tablets. Mylan received final ...

Forest Laboratories has announced it will discontinue sale of NAMENDA tablets on August 15. The company will continue to sell the oral solution of NAMENDA and once-daily extended release capsules.

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . There are no FDA-approved medications for post-traumatic headache. Most patients reported treatment had a ...

Please provide your email address to receive an email when new articles are posted on . Response rates on the SRS-2 and CGI-S were significantly higher in those given memantine. Memantine was also ...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company, today announced that it intends to continue to market both its NAMENDA® ...

DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S. Court of Appeals for the Second Circuit granted the Company's motion to expedite its appeal of a lower court ...

October 2, 2008 (Salt Lake City, Utah) — New trial data suggest that a large 28-mg, once-daily dose of memantine (Namenda, Axura, Forest Pharmaceuticals) in an extended-release formulation may be an ...

MUMBAI--(BUSINESS WIRE)--Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for ...

Aug. 25, 2005 — The U.S. Food and Drug Administration (FDA) has approved once-daily perindopril erbumine tablets for use alone or in combination with concurrent therapy to reduce the risk of ...